Adhesion Molecule Targeted Therapy for Non-Infectious Uveitis

• Published in: International journal of molecular sciences Vol. 23; no. 1; p. 503
• Main Authors: Chen, Yi-Hsing, Lightman, Sue, Eskandarpour, Malihe, Calder, Virginia L
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 03.01.2022; MDPI
• Subjects: Acuity; adhesion molecule; Antigens; CD4 antigen; Cell activation; Cell adhesion; Cell adhesion & migration; Cell Adhesion Molecules; Clinical trials; Disease; E-selectin; Endothelium; Experimental autoimmune uveitis; Experimental autoimmune uveoretinitis; Eye diseases; FDA approval; Humans; Immune system; Inflammation; Inflammatory bowel disease; integrin; Intercellular adhesion molecule 1; Leukocytes; LFA-1 antigen; Ligands; lymphocyte function-associated antigen-1 (LFA-1); Lymphocytes; Lymphocytes T; Medical research; Molecular Targeted Therapy; Monoclonal antibodies; P-selectin; Recruitment; Review; Uveitis; Uveitis - metabolism; Uveitis - therapy; Vascular cell adhesion molecule 1; Vasculitis; very late antigen-4 (VLA-4); Visual acuity; VLA-4 antigen; very late antigen-4 (VLA-4); intercellular cell adhesion molecule-1 (ICAM-1); experimental autoimmune uveitis; selectin; adhesion molecule; integrin; uveitis; vascular cell adhesion protein 1 (VCAM-1); non-infectious uveitis; lymphocyte function-associated antigen-1 (LFA-1)
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms23010503

Non-infectious uveitis (NIU) is an inflammatory eye disease initiated via CD4 T-cell activation and transmigration, resulting in focal retinal tissue damage and visual acuity disturbance. Cell adhesion molecules (CAMs) are activated during the inflammatory process to facilitate the leukocyte recruitment cascade. Our review focused on CAM-targeted therapies in experimental autoimmune uveitis (EAU) and NIU. We concluded that CAM-based therapies have demonstrated benefits for controlling EAU severity with decreases in immune cell migration, especially via ICAM-1/LFA-1 and VCAM-1/VLA-4 (integrin) pathways. P-selectin and E-selectin are more involved specifically in uveitis related to vasculitis. These therapies have potential clinical applications for the development of a more personalized and specific treatment. Localized therapies are the future direction to avoid serious systemic side effects.